Sexual dysfunctions in schizophrenia: Professionals and patients perspectives

Tharoor, Hema; Kaliappan, Anandhalakshmi; Gopal, Subhashini

doi:10.4103/0019-5545.148532

Cited by 24 publications

(17 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Again, cross-cultural factors are probably important, as an investigation in India, using the PRSexDQ-SALSEX questionnaire, found that most patients (91.7%) reported good to fair tolerance of any sexual side effects 28 .…”

Section: Influence Of Treatment Of Psychosis On Sexualitymentioning

confidence: 99%

The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management

2018

View full text Add to dashboard Cite

Sexual dysfunction often accompanies severe psychiatric illness and can be due to both the mental disorder itself and the use of psychotropic treatments. Many sexual symptoms resolve as the mental state improves, but treatment-related sexual adverse events tend to persist over time, and are unfortunately under-recognized by clinicians and scarcely investigated in clinical trials. Treatment-emergent sexual dysfunction adversely affects quality of life and may contribute to reduce treatment adherence. There are important differences between the various compounds in the incidence of adverse sexual effects, associated with differences in mechanisms of action. Antidepressants with a predominantly serotonergic activity, antipsychotics likely to induce hyperprolactinaemia, and mood stabilizers with hormonal effects are often linked to moderate or severe sexual dysfunction, including decreased libido, delayed orgasm, anorgasmia, and sexual arousal difficulties. Severe mental disorders can interfere with sexual function and satisfaction, while patients wish to preserve a previously satisfactory sexual activity. In many patients, a lack of intimate relationships and chronic deterioration in mental and physical health can be accompanied by either a poor sexual life or a more frequent risky sexual behaviour than in the general population. Here we describe the influence of psychosis and antipsychotic medications, of depression and antidepressant drugs, and of bipolar disorder and mood stabilizers on sexual health, and the optimal management of patients with severe psychiatric illness and sexual dysfunction.

show abstract

Section: Influence Of Treatment Of Psychosis On Sexualitymentioning

confidence: 99%

The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management

2018

View full text Add to dashboard Cite

show abstract

“…Our study highlights the need for checking sexual dysfunction in this patients. 16 On one hand schizophrenia is associated with sexual dysfunction while on the other medicines used for its treatment i.e. antipsychotics are also well known to cause sexual dysfunction.…”

Section: Discussionmentioning

confidence: 99%

Use of neuro-psychiatry medicines in patients with sexual dysfunction: a retrospective study

Mutha

Kulkarni

Beldar

et al. 2017

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The objective of the study was to understand the usage of neuro-psychiatry medicines in patients presenting with symptoms of sexual dysfunction.Methods: Medical records of adult patients consulting in the clinic out patients with symptoms of sexual dysfunction were screened for prescriptions of neuropsychiatry medicines. Common neuropsychiatric co-morbidities and prevalence of usage of medicines used for treating neuro-psychiatric disorders was calculated.Results: A total of 628 patients with sexual disorders were included of which 57 (9.1%) had received at least one neuro-psychiatry medicine at the time of presentation. Three most common sexual problems were unconsummated marriage 16 (28.1%), psychogenic ED 14 (24.6%) and organic erectile dysfunction 8 (14.0%). A total of erectile dysfunction 46 (7.3%) patients had psychiatric comorbidity. Five most common neuropsychiatric co-morbidities were anxiety 14 (30.4%), schizhophrenia 10 (21.7%), stress 7 (15.2%), depression 6 (13.0%) and epilepsy 2 (4.3%). The most commonly used neuro-psychiatry medicines were fluoxetine 15 (19.7%), risperidone 11 (14.5%), clonazepam 10 (13.2%), escitalopram 9 (11.8%), alprazolam 5 (6.6%), olanzapine 5 (6.6%) and gabapentin 4 (5.3%). Amisulpride was used in 3 (3.9%) patients whereas valproate, fluoxamine, diazepam and paroxetine were used in 2 (2.6%) patients each. Phenytoin, imipramine, carbamazepine, venlafaxine, haloperidol and sertarline were used in one patient each.Conclusions: Anxiety, schizophrenia and depression are the most common neuropsychiatric disorders in patients with sexual dysfunction. Many patients presenting with sexual dysfunction are already on neuropsychiatry medicines. Further studies are required to evaluate the association between neuropsychiatry medicines and sexual dysfunction in Indian patients.

show abstract

“…Psychiatric disease is among the most important risk factors for women's sexual dysfunction [26][27][28][29]. Women with schizophrenia and schizophrenia spectrum disorders reported a very high burden of sexual dysfunction, with 60-80% of women being affected [30][31][32][33][34][35]. In addition, antipsychotic medications, symptoms of psychosis, institutionalization and societal stigma are all likely contributory factors [36].…”

Section: Introductionmentioning

confidence: 99%

What is the “weight” of body mass index on sexual functioning in women? A mediation model

et al. 2020

View full text Add to dashboard Cite

Purpose It is well known that body mass index (BMI) affects how individuals perceive their well-being and that obese individuals tend to report poorer levels of subjective health status. The aim of this study was to compare subjects with and without FSD and to examine the direct and indirect impact of BMI on female sexual dysfunction (FSD) in overweight/obese and normal-weight women. Methods A cross-sectional study was conducted on 186 overweight/obese and 233 normal-weight women. FSD assessed with the Female Sexual Function Index (FSFI) was investigated in relation to body satisfaction assessed with the Body Uneasiness Test (BUT-A) and self-esteem assessed with the Rosenberg Self-Esteem scale (RSE). Results No difference in the prevalence of FSD was found between overweight/obese (44.4%) and normal-weight women (55.6%), even though significant between-group differences in body image were found. Structural Equation Modelling (SEM) showed that BMI contribute to FSD only through the mediating role of body dissatisfaction and self-esteem. Conclusions The present results support the notion that sexual functioning is not related directly to BMI in women but to a more complex interactions of body weight, satisfaction with one’s own body image, and levels of self-esteem. Clinicians should take into account that for women having a good sexual life seems not related to body weight but to the way their body weight is perceived within the context of self-image. Level of evidence Level III, case–control analytic study.

show abstract

Sexual dysfunctions in schizophrenia: Professionals and patients perspectives

Cited by 24 publications

References 12 publications

The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management

The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management

Use of neuro-psychiatry medicines in patients with sexual dysfunction: a retrospective study

What is the “weight” of body mass index on sexual functioning in women? A mediation model

Contact Info

Product

Resources

About